InspireMD, Inc. (NSPR) to Present Positive MASTER Trial Results at TCT Scientific Symposium
Medical device company InspireMD is slated to present the initial results of its 433-patient randomized MASTER trial later this month at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Miami, Fla. On October 24, Gregg W. Stone, MD, will highlight the company’s MGuard™ embolic protection stent platform technology and its MASTER (MGuard forAcute ST Elevation Reperfusion) study, which demonstrated a positive outcome in patients suffering heart attacks as compared to commercially approved bare metal or drug-eluting stents. CE Mark-approved MGuard™ Embolic Protection Stent is a coronary stent integrated with a proprietary Micronet technology, which is designed to hold…